The recent approval of pembrolizumab (Keytruda) in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) following progression on a platinum-based chemotherapy was a significant advancement for the disease.
Immunotherapy is a big change for head and neck cancer, but one question still remains - will there be a role for these agents in first-line therapy for patients with metastatic recurrent disease who have not previously failed a platinum-based approach.
Read the interview here.
No comments:
Post a Comment